多重耐药菌感染的治疗策略1.pptx

多重耐药菌感染的治疗策略;2;The Greek View of the Appropate Definitions Basedon the Chaos of Resistance Mechanisms;WHO发布全球耐药性细菌报告：情况极为严峻！;5;2005-2014年CHINET VRE 检出率;2014年CHINET 粪肠球菌(3129株)和屎肠球菌(3312株)的耐药率（%）;Proportion MRSA isolates in EU;2005-2014年CHINET 金葡菌中MRSA检出率;2014年CHINET MSSA(4022株)与MRSA(3172株)的耐药率（%）;Untreatable and hard-to-treat infections from carbapenem-resistant Enterobacteriaceae (CRE) bacteria are on the rise among patients in medical facilities. Almost half of hospital patients who get bloodstream infections from CRE bacteria die from the infection ;Proportion of Carbapenems Resistant (R+I) Klebsiella pneumoniae Isolates in EU;CHINET 2005～2014 CRE的检出情况;2005-2014年CHINET耐药监测肺炎克雷伯菌碳青霉烯类耐药率（%）;2014年CHINET 11308株克雷伯菌属耐药率（%）;2005-2014年CHINET耐药监测不动杆菌属碳青霉烯类耐药率（%）;2014年CHINET 8769株不动杆菌属(鲍曼不动93.0%) 的耐药率（%）;Proportion of Carbapenems Resistant (R+I) Pseudomonas aeruginosa Isolates in EU;2005-2014年CHINET耐药监测铜绿假单胞菌对碳青霉烯类的耐药率（%）;2014年CHINET 7471株铜绿假单胞菌耐药率（%）;2005-2014年CHINET碳青霉烯类耐药肠杆菌属;2014年CHINET 3418株肠杆菌属细菌耐药率（%）;肠杆菌科细菌耐药现状;非发酵菌耐药现状;多粘菌素;多粘菌素Colistin: 凤凰涅槃？;Studies that primarily assessed the efficacy and/or toxicity of intravenous polymyxins;单因素分析; ;粘菌素;Worldwide reports of colistin heteroresistance and resistance of A. baumannii;TigecyclineThe Obscure Position in The Real World of Multidrug-Resistance;Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013 ;Antimicrobial activity of antimicrobial agents against Acinetobacter baumannii collected globally between 2004 - 2013 ;;意大利2004-2011年鲍曼不动杆菌敏感性的变化; ;Probability of target attainment (PTA)of tigecycline by Monte Carlo simulation 模拟;2000 HAP Test Article Administration; ;De Pascale et al. Critical Care 2014, 18:R90;De Pascale et al. Critical Care 2014, 18:R90;De Pascale et al. Critical Care 2014, 18:R90;氨基糖苷类;磷霉素 （Fosfomycin）;协同;Clinical Microbiology and InfectionVolume 17, Issue 8, pages 1135-1141, 2 JUN 2011;谢谢！